Crime and Mental Distress

A recent news report suggests that “Having a mental illness makes people more vulnerable to becoming the victims of a crime.”

We wondered about this, because it sounds just like the incessant and inane psychobabble coming out of the “psychology today” brain mill.

These results are suspicious because the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) lists “Victim of crime” as a mental disorder. So it’s hard to imagine that both “mental illness causes being a victim of crime” and “being a victim of crime causes mental illness.” It’s a no-win situation, and the fact that the DSM is a fraudulent machine used to sell psychiatric drugs does not make it more palatable.

The DSM-5 also has fourteen other diagnoses about being a victim in various abusive situations, and thirteen diagnoses about being the perpetrator of abuse or violence. It would seem that both victims and perpetrators are the focus of a lot of attention; so many ways to prescribe psychiatric drugs known to cause violence.

The study authors are using these questionable results to assert that people with mental illness are more likely to be victims rather than perpetrators of crime, giving the benefit of doubt to those who commit violence and further contributing to the perception of the “dangerous environment” so necessary to the existence of coercive psychiatry.

They are trying to prove that school shooters are not mentally ill, because this taint goes against the massive psychiatric public relations campaign to “stop the stigma of mental illness,” which is really a campaign underwritten by pharmaceutical companies to sell drugs.

The fact is, the real criminals here are psychiatrists and psychologists.

The soaring crime rate began to rise when psychiatrists and psychologists infiltrated the fields of education and law. When you put criminals in charge of crime, the crime rate rises.

If psychiatrists and psychologists actually knew what they were doing, the crime rate would drop. Instead, they conduct sham research about the relationship between crime and mental illness, instead of actually curing people and cementing the safety and security of society.

Real criminals would want to obfuscate the issues and point the finger away from themselves. Guess what? When the criminal mind accuses others, he is likely disclosing his own type of crime. And the fact is, psychiatric drugs cause violence, proven again and again as psych-drug-addled school shooters rage on.

Criminals think everyone else is a criminal, since they cannot envision people being decent. Psychiatrists and psychologists, focusing their attention on crime and illness, fail to observe human decency, and think there is nothing else but crime, deceit, and violence — all to be suppressed with harmful and addictive drugs, electroshock, psycho-surgery, involuntary incarceration, and restraints.

Recommendations

1. Legislative hearings should be held to fully investigate the correlation between psychiatric treatment and violence and suicide.

2. Toxicology testing for psychiatric and even illicit drugs should be mandatory in cases where someone has committed a mass shooting or other serious violent crime.

3. Train law enforcement officers, school security and teachers in the adverse effects of psychotropic drugs in order to recognize that irrational, violent and suicidal behavior in persons they may face could be influenced by these drugs.

4. No student shall be forced to take any psychotropic drug as a requisite of their education, in alignment with Title 20 of United States Code: Chapter 33, “Education of Individuals with Disabilities,” Subchapter II, (25) “Prohibition on mandatory medication.”

Psychiatric Drugs, School Violence, and Big Pharma Cover-Up

A study published June 12, 2018 from the University of Illinois at Chicago suggests that more than one-third (37.2%) of U.S. adults may be using prescription drugs that have the potential to cause depression or increase the risk of suicide.
[JAMA. 2018;319(22);2289-2298. doi:10.1001/jama.2018.6741]

Information about more than 26,000 adults from 2005 to 2014 was analyzed, along with more than 200 commonly prescribed drugs. However, many of these drugs are also available over the counter, so these results may underestimate the true prevalence of drugs having side effects of depression.

In other words, the use of prescription drugs, not just psychiatric drugs, that have depression or suicide as a potential adverse reaction is fairly common, and the more drugs one takes (called polypharmacy), the greater the likelihood of depression occurring as a side effect. “The likelihood of concurrent depression was most pronounced among adults concurrently using 3 or more medications with depression as a potential adverse effect, including among adults treated with antidepressants.”

Approximately 15% of adults who used three or more of these drugs concurrently experienced symptoms of depression or suicidal thoughts, compared with just 5% for those not using any of these drugs. Roughly 7.6% of adults using just one of these drugs reported a side effect of depression or suicidal thoughts during the study period, and 9% for those using two of these drugs. These results were the same whether the drugs were psychotropic or not. Depression was determined by asking nine questions related to the symptoms defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

“Commonly used depression screening instruments, however, do not incorporate evaluations of prescribed medications that have depression as a potential adverse effect.” In other words, so-called depression screening tests can register false positives when the person is taking one or more of roughly 200 prescription drugs.

We thought we should dig a little deeper into this phenomenon.

First, understand that there is no depression “disease”. A person can certainly have symptoms of feeling depressed, but this is not a medical condition in itself. An example of a medical condition with a symptom of depression would be a vitamin B1 (thiamine) deficiency. You don’t fix it with an antidepressant; you fix it with vitamin B1. There are hundreds of medical conditions that may have mental symptoms, just as there are hundreds of drugs that can cause or worsen these symptoms. Finding the actual causes with appropriate clinical tests and then fixing what is found is the correct way to proceed.

This leads to a topic known as CYP450, which stands for Cytochrome P450 enzymes. Cytochrome means “cellular pigment” and is a protein found in blood cells. Scientists understand these enzymes to be responsible for metabolizing almost half of all drugs currently on the market, including psychiatric drugs.

These are the major enzymes involved in drug metabolism, which is the breakdown of drugs in the liver or other organs so that they can be eliminated from the body once they have performed their function.

If these drugs are not metabolized and eliminated once they have done their work, they build up and become concentrated in the body, and then act as toxins. The possibility of harmful side effects, or adverse reactions, increases as the toxic concentration increases. The ballpark estimate is that each year 2.2 million Americans are hospitalized for adverse reactions and over 100,000 die from them.

Some people are deficient in CYP450 or have diminished capacity to metabolize these drugs, which may be a genetic or other issue. Individuals with no or poorly performing CYP450 enzymes are much more likely to suffer the side effects of prescription drugs, particularly psychiatric drugs known to have side effects of depression, violence and suicide.

These metabolic processes are immature at birth and up to three years old, and this may result in an increased risk for drug toxicity in infants and young children. Furthermore, certain drugs or certain excipients in vaccines may inhibit activation of CYP450 enzymes, again resulting in an increased risk for the accumulation of non-metabolized drugs and the resultant increase in adverse side effects such as depression, violence and suicide.

The side effects caused by a CYP450 deficiency and its subsequent failure to metabolize any one of hundreds of drugs can then be misdiagnosed as a mental illness, the patient then being prescribed more psychiatric drugs in a mistaken attempt to treat those side effects, further complicating the problems.

It is estimated that 10% of Caucasians and 7% of African Americans are Cytochrome P450 deficient.

The psychiatric and pharmaceutical industries have been aware of this phenomenon for some time, yet they have continued to push psychiatric drugs at an ever increasing rate, and the dramatic increase in symptoms of depression, suicide, and school violence is a direct result.

No one should be prescribed these types of drugs without adequate testing for a CYP450 deficiency, in order to determine their risk potential for adverse reactions. The test is not “standard of care” so one has to ask for it; but beware, they will still recommend an alternative drug if the original one cannot be easily metabolized. Better yet, stop prescribing all psychiatric drugs and find out with proper medical, clinical tests what the real problems are and treat those. Full informed consent is always indicated.

Any psychiatrist or pharmaceutical company that has knowingly withheld evidence about the relationship between CYP450 enzymes and drug side effects should be subject to both prosecution and litigation.

Medical students should be educated about these relationships.

For more information click on any of the links in this newsletter.

Nuedexta, PCP in Disguise

Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) marketed by Avanir Pharmaceuticals is FDA approved for the treatment of PseudoBulbar Affect (PBA), a so-called neurological condition thought to cause involuntary, sudden, and frequent episodes of crying and/or laughing, observed with patients having amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), strokes, or traumatic brain injury. It was originally approved in 2010 by the FDA for such emotional instability.

Dextromethorphan may cause serotonin syndrome, a buildup of an excessive amount of serotonin in the body, and this risk is increased by overdose, particularly if taken with other serotonergic agents, SSRIs or tricyclic antidepressants.

Side effects of serotonin syndrome can be altered mental status, muscle twitching, confusion, high blood pressure, fever, restlessness, sweating, tremors, or shivering. Use of Nuedexta with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants increases the risk of these side effects.

These are not all the possible side effects.

The quinidine in the formula is used to suppress metabolism of the dextromethorphan in order to increase the bioavailability of the dextromethorphan, and is not part of the treatment for PBA. Dextromethorphan acts on the central nervous system, but the mechanism by which dextromethorphan exerts any therapeutic effects in patients with PBA is totally unknown — it’s just a guess from clinical observations that it might have such a symptomatic effect.

Dextromethorphan, derived from an opioid analgesic, is sometimes referred to as DXM or the poor man’s PCP (phencyclidine, or Angel Dust), and is also used recreationally — acting as a dissociative anesthetic producing hallucinogenic states, delusions, or paranoia. At high concentrations, DXM can result in a false-positive for PCP on a drug screen. It is a nonselective serotonin reuptake inhibitor. Its previous primary use since 1958 is as a cough suppressant. Regular use over a long period of time can cause withdrawal symptoms. DXM is often used as a substitute for marijuana, amphetamine, and heroin by drug abusers, and its use as an antitussive (cough suppressant) is now known to be less beneficial than originally thought.

We think that part of the danger of this drug is that it can be prescribed for various symptoms in the Diagnostic and Statistical Manual of Mental Disorders (DSM) just because of its claims of symptomatic relief — in spite of the fact that its mechanism of operation is unknown, its use can be severely abused, and its side effects can be fatal; and the symptoms of its side effects as well as the original medical issues can lead to the prescription of other dangerous and addictive psychiatric drugs.

Examples of DSM diagnoses that may be involved are “Histrionic personality disorder”, “High expressed emotion level within family”, “Adjustment disorder, With mixed disturbance of emotions and conduct”, and “Unspecified mental disorder due to another medical condition”.

Nuedexta is not thought of or advertised as a psychotropic drug, but exposing its camouflage one can now see that essentially it is psychoactive and should be avoided — another example of a psychiatric drug disguised as a legitimate medical drug.

Click here for more information about dangerous psychiatric drugs.

The Manufactured Crisis of Prescription Drug Prices

“Manufactured Crisis – How Devastating Drug Price Increases Are Harming America’s Seniors”

This report was prepared in 2018 by the U.S. Senate Homeland Security & Governmental Affairs Committee Minority Office as requested by Senator Claire McCaskill of Missouri.

It examines the history of rising drug prices between 2012 and 2017 for the twenty brand-name drugs most commonly prescribed for seniors.

Drugs were identified using data from Medicare Part D, and average prices were statistically calculated to come up with annual weighted average wholesale acquisition costs.

Of the twenty drugs in the report, two are used off-label for psychiatric purposes:
§ Lyrica (pregabalin), approved for controlling epileptic seizures and neuropathic pain, is also used off-label as an anti-anxiety drug; it carries a warning that it may cause suicidal thoughts or actions.

§ Synthroid (levothyroxine), a synthetic thyroid hormone approved for hypothyroidism, is also used off-label as an antidepressant, although a specific, causally significant hormonal deficiency has not been identified for depression; it has potential side effects of hair loss, mental and mood changes such as depression, easily broken bones, heart problems, and seizures.

A Lyrica prescription rose in average cost between 2012 and 2017 from $264 to $600 (a 127% increase), while the number of prescriptions rose from 9.1 million to 10.3 million (a 14% increase).

A Synthroid prescription rose in average cost between 2012 and 2017 from $96 to $153 (a 60% increase), while the number of prescriptions dropped from 23.0 million to 18.4 million (a 20% drop).

The report concludes, “Soaring pharmaceutical drug prices remain a critical concern for patients and policymakers alike. Over the last decade, these significant price increases have emerged as a dominant driver of U.S. health care costs.”

Frankly, we do not have a particular bone to pick about the cost of prescription drugs; what does concern us more is the off-label use of medical drugs for fraudulent psychiatric conditions, and the seriousness of their potential side effects. If this concerns you as well, please let Senator McCaskill know your thoughts about this.

We recommend informed consent for any treatment plan. Protect yourself, your family and friends, with full informed consent. Courts have determined that informed consent for people who receive prescriptions for psychotropic (mood-altering) drugs must include the doctor providing information about possible side effects and benefits, ways to treat side effects, and risks of other conditions, as well as information about alternative treatments.

Many People Taking Antidepressants Discover They Cannot Quit

The New York Times had an article April 7, 2018 discussing the fact that antidepressants are actually addictive and have withdrawal symptoms. Quotes are from this article.

“As far back as the mid-1990s, leading psychiatrists recognized withdrawal as a potential problem for patients taking modern antidepressants.”

On the other hand, CCHR has been making this known since 1969. Psychiatrists have been loathe to admit the addictive nature of antidepressants and other psychotropic (mind-altering) drugs, and euphemistically call the side effects of withdrawing from psychiatric drugs “discontinuation syndrome”.

Drug addiction in the 1960’s became an increasing problem, and when investigated it was found that psychiatrists were pushing drugs and addicting people as a “cure.”

“Long-term use of antidepressants is surging in the United States, according to a new analysis of federal data by The New York Times. Some 15.5 million Americans have been taking the medications for at least five years. The rate has almost doubled since 2010, and more than tripled since 2000.”

Nearly 25 million adults have been on antidepressants for at least two years, a 60 percent increase since 2010.

“Many who try to quit say they cannot because of withdrawal symptoms they were never warned about.”

We recommend Informed Consent. Protect yourself, your family and friends, with full informed consent. Courts have determined that informed consent for people who receive prescriptions for psychotropic (mood-altering) drugs must include the doctor providing information about possible side effects and benefits, ways to treat side effects, and risks of other conditions, as well as information about alternative treatments.

“Antidepressants are not harmless; they commonly cause emotional numbing, sexual problems like a lack of desire or erectile dysfunction and weight gain.”

“Patients who try to stop taking the drugs often say they cannot. In a recent survey of 250 long-term users of psychiatric drugs — most commonly antidepressants — about half who wound down their prescriptions rated the withdrawal as severe. Nearly half who tried to quit could not do so because of these symptoms.”

“The truth is that the state of the science is absolutely inadequate … We don’t have enough information about what antidepressant withdrawal entails, so we can’t design proper tapering approaches.”

Polypharmacy is another significant problem, wherein a patient is prescribed many, possibly negatively-interacting drugs, often by multiple doctors who might be unaware of each other’s prescription orders. Often, these are drugs that the patient has been taking for a long period; they may be affecting the patient’s health negatively or are simply no longer beneficial. This is often addressed by deprescribing, which is the process of reducing the medication burden of a patient who might no longer need one or more of their prescriptions. Deprescribing principles are intended to improve health care for the patient by minimizing the harm and costs associated with polypharmacy, and minimizing the withdrawal effects of stopping one or more drugs.

Medications that may be considered for discontinuation include drugs that are no longer indicated, drugs that pose a risk for untoward side effects, drugs that interact adversely, drugs that are given to mitigate the side effects of another drug, and addictive drugs that have withdrawal side effects. However, addictive drugs should never be discontinued abruptly, since the withdrawal side effects can be severe.

For more information about how to safely withdraw from these harmful and addictive psychiatric drugs, download and read the booklet Coming Off Psych Drugs Harm Reduction Guide.

Did You Know You Have Been Paying for Drug Company Ads?

Drug companies have too much influence in Washington, D.C. – so it figures we’re one of the only nations in the world that allows both advertising of prescription drugs to consumers and for those ads to be subsidized by taxpayers.

Under current law, drugmakers can fully deduct the cost of television, online, magazine, and radio ads from their taxes—-all while continuing to hike drug prices for all Americans. You might be tired of paying for it with your taxes.

In 2015 alone, drug companies in the U.S. spent more than $6 billion on fully tax-deductible advertising expenses.

According to the Internal Revenue Code “ordinary and necessary” business expenses are tax deductible, including most advertising costs.

The direct-to-consumer advertising (DTCA) of prescription drugs, however, should not be treated the same as other advertising, since in many cases it disperses deceptive information, hinders the patient-doctor relationship, encourages patients to choose drug-based solutions over lifestyle-based ones, reduces the amount spent on research and development, and increases spending on drugs without a corresponding health benefit.

In the case of psychotropic drugs, clearly these ads dispense deceptive information, as we have repeatedly written about. In the face of these compelling public policy justifications, the Tax Code could be revised to deny tax deductions for DTCA. While the First Amendment protects free speech, this protection does not require Congress to continue to subsidize DTCA.

Hence Senate Bill S.2478 has been introduced into Congress – “A bill to amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for prescription drugs” [115th Congress, 2017-2018].

The real problem with the psycho-pharmaceutical industry is that psychiatrists fraudulently diagnose life’s problems as an “illness”, stigmatize unwanted behavior as  “diseases,” and prescribe harmful and addictive drugs to keep patients in the mental health care system. Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful. Why are we continuing to subsidize their advertising? Contact your U.S. Senators to support S.2478.

Mental Health “Care” Coming to Your Community

News articles extolling “Community Mental Health” continue to be published across the United States and abroad. We thought you should know more about this.

These articles generally discuss funding, either the lack or availability of public funding, for various mental health care programs — such as Community Mental Health Centers (CMHC), police Crisis Intervention Teams, Suicide Programs, Veterans Programs, Mental Health Courts, Emergency Management or Crisis Counseling, Violence Prevention, School Safety, or other public/private ventures in the mental health care industry. They also generally complain about the lack of a sufficient number of psychiatrists or psychologists in relation to the target population. Let us help put the record straight about this.

History of CMHC

In 1955, a five-year inquiry by the U.S. Joint Commission on Mental Illness and Health recommended replacing psychiatric institutions with Community Mental Health Centers (CMHCs). According to Henry A. Foley, Ph.D., and Steven S. Sharfstein, M.D., authors of Madness in Government, “Psychiatrists gave the impression to elected officials that cures were the rule, not the exception,” a claim that the psychiatric industry could not and still cannot substantiate.

The advent of Community Mental Health psychiatric programs in the 1960s would not have been possible without the development and use of neuroleptic drugs, also known as antipsychotics, for mentally disturbed individuals. Neuroleptic is from Greek, meaning “nerve seizing”, reflective of how the drugs act like a chemical lobotomy.

These community facilities and programs were promoted as the solution to all institutional problems. The premise, based almost entirely on the development and use of neuroleptic drugs, was that patients could now be successfully released back into society as long as they were taking these drugs. Ongoing service would be provided through government-funded units called Community Mental Health Centers (CMHC). These centers would tend to the patients from within the community, dispensing the neuroleptics that would keep them under control. Governments would save money and individuals would improve faster. The plan was called “deinstitutionalization.”

The first generation of neuroleptics, now commonly referred to as “typical antipsychotics” or “typicals,” appeared during the 1960s. They were heavily promoted as “miracle” drugs that made it “possible for most of the mentally ill to be successfully and quickly treated in their own communities and returned to a useful place in society.”

These claims were false, as neuroleptics are now known to have devastating side effects. In an article in the American Journal of Bioethics in 2003, Vera Sharav stated, “The reality was that the therapies damaged the brain’s frontal lobes, which is the distinguishing feature of the human brain. The neuroleptic drugs used since the 1950s ‘worked’ by hindering normal brain function: they dimmed psychosis, but produced pathology often worse than the condition for which they have been prescribed — much like physical lobotomy which psychotropic drugs replaced.”

Author Peter Schrag wrote in Mind Control, by the mid-seventies enough neuroleptic drugs and antidepressants “were being prescribed outside hospitals to keep some three to four million people medicated fulltime – roughly ten times the number who, according to the [psychiatrists’] own arguments, are so crazy that they would have to be locked up in hospitals if there were no drugs.”

After a decade of the Community Mental Health program, consumer advocate Ralph Nader called it a “highly touted but failing social innovation.” It “already bears the familiar pattern of past mental health promises that were initiated amid great moral fervor, raised false hopes of imminent solutions and wound up only recapitulating the problems they were to solve.”

As for the funding of CMHCs and psychiatric outpatient clinics, the fact is that psychiatry’s budget in the United States soared from $143 million in 1969 to over $9 billion in 1997 – a more than 6,000% increase in funding, while increasing by only 10 times the number of people receiving services. The estimated costs today are over $11 billion.

If collecting these billions in inflated fees for non-workable treatments wasn’t bad enough, in 1990 a congressional committee issued a report estimating that Community Mental Health Centers (CMHCs) had diverted between $40 million and $100 million to improper uses, and that a quarter of all CMHCs had so thoroughly failed to meet their obligations as to be legally subject to immediate recovery of federal funds.

Psychiatrists have consistently blamed the failure of deinstitutionalization on a lack of community mental health funding. In reality, they create the drug-induced crisis themselves and then, shamelessly, demand yet more money.

The CMHCs became legalized drug dealerships that not only supplied drugs to former mental hospital patients, but also supplied psychiatric prescriptions to individuals not suffering from “serious mental problems.” Deinstitutionalization failed and society has been struggling with the resultant homelessness and other disastrous results ever since.

Accompanying the psychiatric push for expanded community mental health programs is their demand for greater powers to involuntarily commit individuals. Psychiatrists disingenuously argue that involuntary commitment is an act of kindness, that it is cruel to leave the disturbed in a tormented state. However, such claims are based on the dual premises that 1) psychiatrists have helpful and workable treatments to begin with, and 2) psychiatrists have some expertise in diagnosing and predicting dangerousness. Both suppositions are patently false.

In spite of receiving huge increases in funding in the United States, psychiatry and psychology not only failed but managed to make things drastically worse; rates of drug abuse, suicide, illiteracy and crime continue to rise.

The real message is this: in spite of an investment of billions of dollars for psychiatric promises, the world has received nothing but presumptuous demands from psychiatric vested interests for more money.

Contact your local, state and federal authorities and legislators and demand that funding for psychiatric promises be revoked until the mental health industry can prove its effectiveness with actual cures.

“Shoot ’em up” Is No Longer Just for Westerns

Once is happenstance, twice is coincidence, three times is enemy action.”
[with thanks to Charles Stross in The Apocalypse Codex.]

The Citizens Commission on Human Rights (CCHR), a mental health watchdog that has investigated school and other mass shootings since the Columbine High School Shooting in 1999, warns about pouring hundreds of millions of dollars into more mental health services in response to the Marjory Stoneman Douglas High School shooting on Valentine’s Day.

An investigation into the shooting must include what psychotropic drugs the alleged shooter, Nikolas Cruz, has been prescribed and the fact that he had apparently undergone “behavioral health” treatment which did nothing to prevent the murderous outcome. A 2016 Florida Department of Children and Family Services report indicated that he was regularly taking “medication” for Attention Deficit Hyperactivity Disorder (ADHD); these types of psychotropic drugs are known to have violence and suicide as potential side effects.

CCHR International’s investigation into school violence reveals that at least 36 school shootings and/or school-related acts of violence have been committed by those taking or withdrawing from psychiatric drugs resulting in 172 wounded and 80 killed.

At least 27 international drug regulatory agency warnings have been issued on psychiatric drugs being linked to mania, violence, hostility, aggression, psychosis, and homicidal ideation (thoughts or fantasies of homicide that can be planned).

Cruz, 19, charged over the Parkland, Florida shooting, is a prime example of the failure of the mental health system. Expecting better mental health treatment to solve these problems is a forlorn hope, since it promises something that has not and cannot be delivered.

Pouring more funds into a mental health system that keeps failing and continues to use “treatments” that may induce violent and suicidal behavior in a percentage of those taking them, is a recipe for future disaster. Recognize that the repeated violence caused by psychiatric drugging of school children is neither happenstance nor coincidence, and is in fact an enemy action, and the enemy is psychiatry.

The survivors of the Parkland shooting, the families of those killed and the community at large deserves answers and accountability. CCHR is calling on families with knowledge of a loved one who has experienced treatment abuse and for whistleblowers who have concerns about any behavioral facility to contact CCHR by reporting the abuse here.

For more information read this news release.

Vraylar to the Vrescue

We are now seeing TV ads for Vraylar (generic cariprazine) for “manic or mixed episodes of bipolar I disorder.” An atypical antipsychotic, it alters levels of dopamine and serotonin in the brain. Vraylar was first approved by the FDA to treat schizophrenia in 2015. It can be compared to the antipsychotic risperidone, which is now available as a generic and thus not as expensive as the newer drug Vraylar. They say cariprazine is “less risky” than risperidone, but we think it was approved because it is more expensive.

Hungarian drugmaker Gedeon Richter, the developer of the drug, licensed it to the Dublin pharmaceutical company Allergan and receives royalties on its sales. It cost about $400 million to develop, and its projected income at the time was $300 million per year. Allergan’s Vraylar revenue for 2017 was $287.8 million. A month’s supply for one person costs approximately $1,050 (depending on dosage.)

The exact way Vraylar is supposed to work is totally unknown. It is another example of the debunked medical model of psychiatry which fraudulently supposes that messing with the levels of neurotransmitters in the brain can help. The prevailing psychiatric theory is that mental disorders result from a chemical imbalance in the brain; however, there is no biological or other evidence to prove this.

Basically, psychiatrists gave it in clinical trials to a bunch of people with mental disturbances and performed extensive statistical analyses to “prove” that symptoms of mental distress were less severe while taking the drug than while taking a placebo; while at the same time recording, but discounting, all the adverse reactions.

The most common side effects during clinical tests were uncontrolled movements of the face and body (tardive dyskinesia), muscle stiffness, indigestion, vomiting, sleepiness, and restlessness (akathisia). Other possible side effects are stroke, neuroleptic malignant syndrome, falls, seizures, agitation, anxiety — basically most of the adverse reactions we’ve come to associate with similar psychotropic drugs. This particular formulation stays in the body for weeks even after you stop taking it, so that side effects may occur long after you start or stop taking it.

During clinical trials, 12% of the patients who received Vraylar for a diagnosis of bipolar I discontinued treatment due to an adverse reaction. They say that the drug is not habit-forming, but it has withdrawal symptoms. The trials did not run long enough to actually test for physical addiction, although withdrawal symptoms were reported in newborns whose mothers were exposed to it during the third trimester of pregnancy. Also, the drug carries a black box warning that elderly patients with dementia-related psychosis are at an increased risk of death, just like any other atypical antipsychotic.

“Bipolar I disorder” used to be called “manic-depressive”. All it means is that a person roller-coasters — sometimes being up and other times being down. Bipolar disorder is characterized by unusual shifts in a person’s mood, energy and ability to function. Its symptoms are severe mood swings from one extreme of overly high or irritable (mania) to sad and hopeless (depression), then back again. In the 1800s, bipolar was known as manic depression, a term invented by German psychiatrist Emil Kraepelin. In 1953, another German psychiatrist, Karl Kleist coined the term “bipolar.” There is no objective clinical medical test for the condition.

Psychiatric treatment for schizophrenia and bipolar is complicated by high rates of relapse, indicating that the treatments do not really work. The failures to adequately treat bipolar apparently caused the psychiatric industry to split up the diagnosis into bipolar I and bipolar II, where bipolar II means that the individual has not experienced a full manic episode, just an elevated state of irritable mood that is less severe than a full manic episode. It’s splitting a hair that is completely irrelevant to anything except which drug to prescribe.

An estrogen imbalance, hypoglycemia (abnormal decrease in blood sugar), allergies, caffeine sensitivity, thyroid problems, vitamin B deficiencies, stress, and excessive copper in the body can all cause the symptoms fraudulently labeled as  “bipolar disorder.”

“Schizophrenia,” “bipolar,” and all other psychiatric labels have only one purpose: to make psychiatry millions in insurance reimbursement, government funds and profits from drug sales. If you are told that a psychiatric condition is due to a brain-biochemical imbalance, ask to see the test results.

The global bipolar drug market is growing, possibly due to increasing stress in life. For information about how stress can cause someone to roller-coaster, see our blog here. Click here for more information about bipolar, and here for more information about schizophrenia.

Missouri Foster Care Children at Risk

Following up on the federal class action lawsuit (M.B. v. Corsi) against the Missouri Department of Social Services for the overuse of harmful and addictive psychotropic drugs among vulnerable foster children.

More than 30 percent of Missouri’s 13,000 foster children are on at least one psychotropic medication, with 20 percent taking two or more psychotropic medications at the same time. This is almost twice the national rate of such prescriptions. These drugs are known to cause violence and suicide, as well as being addictive.

For the first time, a federal court has ruled that the failure to oversee the administration of powerful psychotropic medications to children in foster care could violate their rights under the Constitution.

On January 8, 2018 U.S. District Judge Nanette Laughrey denied the state’s motion to dismiss the children’s due process claims. The judge was particularly concerned that the state, by its own admission, fails to maintain complete medical records for the foster children in its care, and does not provide updated health information to foster parents or doctors.

Foster children are drugged with harmful psychotropics at 13 times the rate of children living with their parents.

Recognize that the real problem is that psychiatrists fraudulently diagnose children’s problems as an “illness”, and stigmatize unwanted behavior or study problems as “diseases.” Psychiatry’s stigmatizing labels, programs and treatments are harmful junk science; their diagnoses of “mental disorders” are a hoax – unscientific, fraudulent and harmful.

Click here for more information about psychiatric drugs harming foster care children.